LOS ANGELES, March 12, 2026 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between March 26, 2025 and November 4, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before May 5, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Soleno downplayed evidence of safety concerns revealed by its Phase 3 clinical trial of diazoxide choline extended-release tablets (“DCCR”). The Company’s DCCR treatment suffered from greater safety risks than it had disclosed. The Company’s DCCR had lower commercial viability and heightened risk of adverse events. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Soleno, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/slno-investors-have-opportunity-to-lead-soleno-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302711873.html
SOURCE The Schall Law Firm
